ARTICLE | Company News
Mabtech, Sorrento deal
September 7, 2015 7:00 AM UTC
Mabtech granted Sorrento exclusive rights to develop and commercialize four undisclosed biosimilar mAbs in North America, Europe and Japan. The antibodies have completed Phase III testing. Sorrento sa...